Alligator Bioscience AB (OSTO:ATORX)
kr 0.558 0.012 (2.2%) Market Cap: 422.99 Mil Enterprise Value: 385.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Q1 2022 Alligator Bioscience AB Earnings Call Transcript

Apr 27, 2022 / 01:30PM GMT
Release Date Price: kr1.13 (+1.63%)
SÃ;ren Bregenholt
Alligator Bioscience AB - CEO

¸ -

Thank you and welcome to this interim report call from Alligator Bioscience. My name is Søren Bregenholt, the CEO of the Alligator Bioscience. And with me today, I have our Chief Financial Officer, Marie Svensson. Before we get into the actual call, if we could have the disclaimer, I want to remind you that during this call there will be forward-looking statements, both on the financial performance and the actual project performance of the company.

If we go to slide number 3, I just wanted to highlight some of the priorities that we -- and some of the milestones that Alligator achieved during 2021, allowing us to go into 2022 in a strong position. First of all, we initiated Phase II clinical development with our lead asset, Mitazalimab, in first-line pancreatic cancer patients in combination Folfirinox chemotherapy; Phase I assets, 1017, we reported positive biomarker data, and the intention to move -- and safety data and the intention to move forward to Phase II.

We presented several collaborations during the year

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot